Immunai

Immunai is happy to be contributing via our single cell multi-omics platform and AI engine to the presentation of AstraZeneca’s Volrustomig (MEDI5752, PD1/CTLA-4 Bispecific) in 1L RCC @ESMO2023. Congrats to AstraZeneca on a successful #ESMO2023 presentation. https://lnkd.in/dEJbSPqA

In a recent publication featured in @Nature, our team collaborated with Genentech on the multiomic single-cell analysis of the Tiragolumab cohort, presented in Figure 3. Thank you to the patients and collaborators, as well as our dedicated team at Immunai. Read the full article here: https://lnkd.in/drsg9Tp2

In a recent publication featured in @Nature, our team collaborated with Genentech on the multiomic single-cell analysis of the Tiragolumab cohort, presented in Figure 3. Thank you to the patients and collaborators, as well as our dedicated team at Immunai. Read the full article here: https://lnkd.in/drsg9Tp2

Yesterday our very own Tali Raveh, VP R&D, discussed at the Biomed Israel 2024 conference how Immunai harnesses immunomics to improve therapeutic decision-making

We’re excited to share that Immunai was selected as the winner of the atlas award in the healthcare and life science category. The Atlas Award is given annually, since 2016, to Israeli start-up companies that create technology, an idea, or a product of exceptional value, in Israel and around the world. The winners are chosen based on innovation, boundary breaking, and world wide value generation.

"Our starting point was creating what I call the Google Maps for the immune system," – Noam Solomon In a recent interview with Zach Winn from MIT Technology Review, our co-founder and CEO, Noam Solomon, discussed how we’re helping to predict a patient’s response to treatments by building a comprehensive map of the immune system. Using AMICA™, our detailed immune system database, our “map” is refining patient treatment and fostering more successful clinical trials in the pharmaceutical industry. Read the full article to see how we’re harnessing the power of big data to forge a new path in drug development and personalized medicine: https://lnkd.in/dmkde-yJ

Meet our team at #AACR!

Attending #AACR in San Diego next week? We’d love to meet with you! If you’re interested in connecting with our CEO Noam Solomon or discussing how we are mapping the immune system and delivering machine learning insights to advance drug development reach out info@immunai.com. Learn more about Immunai here: https://www.immunai.com/ #AACR24 #Biotech #Cancer #Oncology American Association for Cancer Research

Our team in Israel was excited to celebrate the five year founding of Immunai by moving into our new office.  Thank you to our dedicated operations team that made this possible!  We are optimistic that our new environment will inspire us to continue to develop solutions that improve patients’ lives. 

Our team in Israel was excited to celebrate the five year founding of Immunai by moving into our new office.  Thank you to our dedicated operations team that made this possible!  We are optimistic that our new environment will inspire us to continue to develop solutions that improve patients’ lives.